AstraZeneca wins shareholder backing for NYSE listing in US pivot

Core Viewpoint - AstraZeneca shareholders have approved a direct listing of the company's shares on the New York Stock Exchange, which will provide access to a deeper capital pool [1] Group 1 - The approval from shareholders marks a significant step for AstraZeneca in enhancing its market presence [1] - The direct listing is expected to facilitate greater liquidity and attract a broader range of investors [1] - This move aligns with the trend of pharmaceutical companies seeking to optimize their capital structures through public listings [1]